



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn20>

### Direct Regioselective Enzymatic Acylation of Nucleosides: Building-Blocks for the Solution Phase Synthesis of Oligonucleotides

Javier García <sup>a</sup>, Susana Fernández <sup>a</sup>, Miguel Ferrero <sup>a c</sup>, Yogesh S. Sanghvi <sup>b</sup> & Vicente Gotor <sup>a</sup>

<sup>a</sup> Departamento de Química Orgánica e Inorgánica, Facultad de Química, Universidad de Oviedo, Oviedo, Spain

<sup>b</sup> Manufacturing Process Department, Isis Pharmaceuticals, Carlsbad, California, USA

<sup>c</sup> Departamento de Química Orgánica e Inorgánica, Facultad de Química, Universidad de Oviedo, Avenida Julián de Clavería, 8, E-33006, Oviedo, Spain

Published online: 31 Aug 2006.

To cite this article: Javier García, Susana Fernández, Miguel Ferrero, Yogesh S. Sanghvi & Vicente Gotor (2003) Direct Regioselective Enzymatic Acylation of Nucleosides: Building-Blocks for the Solution Phase Synthesis of Oligonucleotides, *Nucleosides, Nucleotides and Nucleic Acids*, 22:5-8, 1455-1457, DOI: [10.1081/NCN-120023009](https://doi.org/10.1081/NCN-120023009)

To link to this article: <http://dx.doi.org/10.1081/NCN-120023009>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

## Direct Regioselective Enzymatic Acylation of Nucleosides: Building-Blocks for the Solution Phase Synthesis of Oligonucleotides

Javier García,<sup>1</sup> Susana Fernández,<sup>1</sup> Miguel Ferrero,<sup>1,\*</sup>  
Yogesh S. Sanghvi,<sup>2</sup> and Vicente Gotor<sup>1</sup>

<sup>1</sup>Departamento de Química Orgánica e Inorgánica, Facultad de Química,  
Universidad de Oviedo, Oviedo, Spain

<sup>2</sup>Manufacturing Process Department, Isis Pharmaceuticals,  
Carlsbad, California, USA

### ABSTRACT

The synthesis of 3'- and 5'-*O*-levulinyl nucleosidic monomers through enzymatic acylation with acetonoxime levulinate is demonstrated. The acylation process takes place in one-step and use of expensive reagents, such as DMTrCl is avoided. The regioselectivity of the procedure makes it very convenient for acylated monomers required for solution phase synthesis of oligonucleotides.

### INTRODUCTION

The potential of antisense oligonucleotides for the treatment of a variety of diseases, through sequence-specific modulation of gene expression has been well recognized.<sup>[1]</sup> Chemical modifications in oligonucleotides<sup>[2]</sup> have resulted in enhanced

\*Correspondence: Miguel Ferrero, Departamento de Química Orgánica e Inorgánica, Facultad de Química, Universidad de Oviedo, Avenida Julián de Clavería, 8, E-33006 Oviedo, Spain; Fax: +34 98 510 3448; E-mail: mferreo@sauron.quimica.uniovi.es.




nuclease resistance, cellular uptake, and appropriate hybridization to mRNAs or target genes. With the recent success of various antisense oligonucleotides undergoing human clinical trials and possibility of their commercial launch in the near future may require very large quantities of therapeutically useful oligonucleotides. Particularly when multi-kilogram quantities of oligonucleotides are required, solution-phase synthesis appears to be an alternative method of choice instead of traditional solid-phase synthesis.<sup>[3]</sup> The key building blocks for the solution-phase oligonucleotide synthesis are 3'- and/or 5'-*O*-levulinyl nucleosidic monomers.<sup>[4]</sup> The levulinyl group is frequently chosen because it is stable to coupling conditions and can be selectively cleaved, without adversely impacting other protecting groups in the molecule. Until recently, the preparation of these building blocks has been carried out through multiple protection/deprotection steps. For the manipulation of protecting groups, application of biocatalysts in organic synthesis has become an attractive alternative to the conventional chemical methods.<sup>[5]</sup>

Recently, we have reported a short and convenient synthesis of 3'- and 5'-*O*-levulinyl nucleosides from the corresponding 3',5'-di-*O*-levulinyl derivatives by regioselective enzymatic hydrolysis, avoiding several tedious chemical protection/deprotection steps.<sup>[4]</sup> During hydrolysis process, base-protected cytidine and adenosine derivatives were not good substrates for the enzyme *Candida antarctica* lipase B (CAL-B), which afforded the 3'-*O*-levulinyl nucleosides. To overcome this limitation of our earlier work, herein we report for the first time a regioselective enzymatic acylation of various base-protected nucleosides with acetonoxime levulinate using biocatalysts.

## RESULTS AND DISCUSSION

For the enzymatic acylation, acetonoxime levulinate was used as acylating agent due to higher selectivity compared with levulinic anhydride. CAL-B catalyzes the



Scheme 1.

acylation of the 5'-OH of nucleosides **1** and **2** with excellent regioselectivity affording 5'-*O*-levulinyl derivatives **4** and **6**, respectively, in high yields (Sch. 1). In contrast to the hydrolysis process<sup>[4]</sup> base-protected cytidine and adenosine derivatives were adequate substrates for CAL-B during acylation. Nevertheless, when *Pseudomonas cepacia* lipase (PSL-C) is employed, 3'-OH is acylated with high selectivity furnishing 3'-*O*-levulinyl nucleosides **3** and **5**. As observed with the hydrolysis process, the selectivity of PSL-C was lost when acylation of base unprotected or 2'-*O*-methyl nucleosides was attempted. Furthermore, PSL-C did not show selectivity during acylation of guanosine derivatives. Such nucleosides could be prepared by enzymatic hydrolysis, where CAL-B hydrolyzed selectively the 5'-*O*-levulinyl group to afford the 3'-*O*-levulinyl derivatives.

In summary, we have developed an efficient method for the synthesis of 3'- and 5'-*O*-levulinyl protected nucleosides through regioselective enzymatic acylation of the parent nucleosides. It is noteworthy that preparation requires a single step, enzymes can be recycled several cycles, and expensive reagent such as DMTrCl is eliminated. These advantages make the acylation procedure very convenient from an industrial point-of-view. In addition, base-protected cytidine and adenosine derivatives, not available through the hydrolysis process, were now accessible. Both hydrolysis and acylation procedures are complementary to each other and offer an excellent alternative to the conventional method. We are in process of scaling-up these reactions for large-scale applications.

## REFERENCES

1. For a recent monograph on this topic see: *Antisense Drug Technology Principles, Strategies and Applications*; Crooke, S.T. Ed.; Marcel Dekker: New York, 2001.
2. Sanghvi, Y.S. Chapter 7. In *Comprehensive Natural Products Chemistry*; Kool, E.T., Ed.; Elsevier: Amsterdam, 1999; Vol. 7, 285–311.
3. Sanghvi, Y.S. *Org. Process R&D* **2000**, *4*, 168–169.
4. García, J.; Fernández, S.; Ferrero, M.; Sanghvi, Y.S.; Gotor, V. *J. Org. Chem.* **2002**, *67*, 4513–4519.
5. a) Ferrero, M.; Gotor, V. *Chem. Rev.* **2000**, *100*, 4319–4347; b) Ferrero, M.; Gotor, V. *Monatsh. Chem.* **2000**, *131*, 585–616.



